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n	 INTRODUCTION
As more is learned about fibromyalgia (FM), the role of psychosocial fac-
tors becomes increasingly recognised to 
the extent that the condition is now viewed 
as the result of a complex interaction be-
tween biological, psychological and social 
factors. The growing attention towards the 
psychiatric disorders associated with FM is 
also related to consistent findings that un-
recognised and untreated psychopatholo-
gies can significantly increase pain-related 
dysfunction and interfere with successful 
treatment (1). The reciprocally close rela-
tionship between FM and psychopathology 
is further supported by the observation that 
pain hinders the remission of psychiatric 
disorders; for example, in the case of major 
depressive episode, pain delays treatment 
response (2) and is a significant risk factor 
for relapse (3). 
Previous research has shown that FM is 
closely associated with a number of psy-
chiatric disorders and psychopathological 
aspects. In a sample of 115 fifteen females 
with FM, 77.3% had psychiatric illnesses 
diagnosed using the Structured Clinical In-
terview for DSM-IV (SCID I and II), with 
34.8% having a mood disorder and 32.2% 
an anxiety disorder (4). The prevalence of 
mood and anxiety disorders is more than 
three times higher in FM patients than in 
the general population, and match the prev-
alence rates of other pain illnesses such as 
rheumatoid arthritis (RA) (5) and chronic 
back pain (6) in some studies, but not in 
all (7). The frequency of mood disorders 
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summary
Objective. To review the literature addressing the relationship between mood disorders and fibromyalgia/chron-
ic pain and our current understanding of overlapping pathophysiological processes and pain and depression 
circuitry.
Methods. We selectively reviewed articles on the co-occurrence of mood disorders and fibromyalgia/chronic 
pain published between 1990 and July 2012 in PubMed. Bibliographies and cross references were considered 
and included when appropriate. 
Results. Forty-nine out of 138 publications were retained for review. The vast majority of the studies found 
an association between depression and fibromyalgia. There is evidence that depression is often accompanied 
by symptoms of opposite polarity characterised by heights of mood, thinking and behaviour that have a con-
siderable impact on pharmacological treatment. Recent developments support the view that the high rates of 
fibromyalgia and mood disorder comorbidity is generated by largely overlapping pathophysiological processes 
in the brain, that provide a neurobiological basis for the bidirectional, mutually exacerbating and disabling 
relationship between pain and depression. 
Conclusions. The finding of comparable pathophysiological characteristics of pain and depression provides a 
framework for understanding the relationship between the two conditions and sheds some light on neurobio-
logical and therapeutic aspects. 
Key words: Depression, fibromyalgia, pain, comorbidity.
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in patients with FM has led to consider-
ation of common pathophysiological path-
way that may explain the neurobiological 
mechanism that makes them mutually ex-
acerbating and disabling.
In this review, we first describe a selected 
sample of current research studies of the 
association between mood disorders and 
FM/chronic pain, and then consider inves-
tigations into the cerebral pathophysiologi-
cal pathways that may help to shed some 
light on the neurobiological basis of the 
pain/psychopathology interaction.
n	 METHODS
We searched the literature entered in 
PubMed from 1990 to July 2012 using 
the terms “mood disorder,” “depression” 
“major depression,” “bipolar disorder,” 
“chronic pain,” “fibromyalgia”, and “co-
morbidity.” The reference lists of selected 
articles were reviewed for additional pa-
pers of interest that were missed by the 
computerised database search. Each article 
was reviewed, and those providing any 
clinical or pathophysiological information 
concerning the overlapping of FM/chronic 
pain and mood disorders were included. 
n	 RESULTS
Three hundred and twelve studies were 
initially identified as being potentially rel-
evant, of which the full articles of 138 stud-
ies were selected and reviewed. Of these, 
49 were finally identified as focusing on 
the relationship between mood disorders 
and FM/chronic pain, the overlapping 
pathophysiological processes, and the cir-
cuitries of pain and depression. 
Mood disorders
The vast majority of studies and reviews 
have assessed the role of depression in 
chronic pain and FM. It has long been 
known that major depression is highly 
prevalent in patients with FM, with the 
rates of current depressive disorders rang-
ing from 28.6% to 70%, and the life time 
rates ranging from 62% to 86% (8, 9), the 
differences being due to differences in the 
diagnostic assessment of depression and/
or sampling bias. The close relationship 
between the two disorders is further sup-
ported by the fact that FM is the second 
most frequent general medical condition 
associated with major depressive disorder, 
with an odds ratio (OR) of 3.4 (10).
Depressive symptoms beyond formal di-
agnosis of major depressive disorder are 
also frequent in FM patients, with a preva-
lence of about 40% as shown in a commu-
nity study of almost 45,000 subjects (11). 
An even higher rate has been recently re-
ported by Aguglia (12), who found clini-
cally significant depressive symptoms 
(as indicated by a Hamilton Rating Scale 
for Depression (HAM-D) score of >7) in 
83.35% of the FM patients referred to a 
Rheumatology Unit.
Over the last few years, converging evi-
dence has been collected that FM patients 
have high rates of symptoms in the domain 
of the manic/hypomanic component of bi-
polar disorder, which are characterised by 
heights of mood, thinking or activity. Carta 
(13) detected manic symptoms in 59% of 
FM patients, approximately double the rate 
found in a control sample of healthy sub-
jects. These findings were confirmed by the 
study of Dell’Osso (14), who found a high 
rate of lifetime manic symptoms that proved 
to be related to the severity of pain and its 
effect on working activities, as well as to a 
negative impact on overall physical health. 
In a recent study, we found a high rate 
(88%) of so-called ”soft bipolar spectrum 
disorders” in patients with FM: i.e. disor-
ders in which hypomania or hypomanic 
symptoms are associated with major or 
minor depression, or occur in the absence 
of any depressive condition (15). These 
findings suggest that hypomanic symp-
toms (and only secondarily depressive 
symptoms) may be the core expression of 
mood disorders in FM. In the light of these 
observations, the over-active behaviour 
that has been frequently reported (16) to be 
characteristic of FM patients can be seen as 
a manifestation of an hypomanic height of 
activity (goal-directed over-activity).
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Probably related to the high prevalence of 
bipolar spectrum disorder, a prospective 
study of a cohort of 1269 female patients 
with FM found that the risk of suicide was 
ten times higher than in the general popula-
tion (17) and a large-scale community study 
(the NIMH Epidemiologic Catchment Area 
Program) has shown that subjects with sub-
syndromal manic/hypomanic symptoms 
had a four times higher suicide attempt rate 
than a comparative group with no mental 
disorders (18). The high rate of hypomanic 
symptoms has an important clinical impact 
given the increasing off-label use of antide-
pressants to control pain (regardless of the 
presence of depression) in non-psychiatric 
settings. The correct detection of the manic/
hypomanic component of mood dysregula-
tion that leads to a diagnosis in the realm 
of bipolar disorders is crucial, because the 
treatment of bipolar disorder is different 
from that of recurrent major depression. 
Controlled data suggest that there is a risk 
for inducing mania in patients with a bi-
polar spectrum disorder who are treated 
solely with antidepressants (19). Further-
more, their long-term use may have nega-
tive consequences such as a poor treatment 
response (20) or the induction of rapid cy-
cling (21) a severe form of bipolar disorder 
characterised by four or more episodes of 
mania or depression in one year. For these 
reasons, the treatment of bipolar illness 
classically includes the use of so-called 
‘mood stabilisers’ (lithium and specific 
anticonvulsants) and atypical antipsychotic 
agents during both the acute and main-
tenance phases. Antidepressants should 
never be used alone, but always together 
with a mood stabiliser or an atypical anti-
psychotic agent. Although all of the latter 
seem to be effective against acute mania, 
only aripiprazole olanzapine and quetiap-
ine have sufficient data documenting their 
efficacy in preventing relapse in acute re-
sponders (22). 
Ninety percent of the studies considered in 
an evidence-based review (24) concluded 
that atypical antipsychotic agent have an 
analgesic effect in pain conditions ranging 
from headache and cancer pain to chronic 
lower back pain and FM. Four still-unpub-
lished double-blind controlled studies have 
recently evaluated the efficacy of quetiap-
ine alone or as an add-on in the treatment 
of FM. Two of these have been presented 
at congresses, and both suggested that 
quetiapine could be an effective treatment 
for FM (25). 
A positron emission tomography study of 
19 healthy male volunteers provides theo-
retical support for the clinical view that an-
tipsychotic agents (which share the capac-
ity to antagonise dopamine D2 receptors) 
may have analgesic properties because 
it showed that people with relatively few 
available D2 receptors in the forebrain are 
likely to have a higher tonic level of pain 
suppression (26). Moreover, some anticon-
vulsant agents may improve both bipolar 
mood disorders and pain. Pregabalin is an 
anticonvulsant with demonstrated effects 
on key symptoms of FM such as pain, sleep 
and fatigue, and has been approved for its 
management in the United States (27). It 
has also been observed that pregabalin im-
proves anxiety, a condition that frequently 
co-occurs with bipolar disorders (28). Val-
proate and carbamazepine, which are used 
during both the acute and maintenance 
phases of bipolar disorder, all have U.S. 
Food and Drug Administration (FDA) in-
dications for the treatment and/or prophy-
laxis of some painful conditions (e.g., mi-
graine or trigeminal neuralgia, neuropathic 
pain and FM) (29).
Effect of mood on pain processing
The effect of mood on pain processing in 
FM patients is an important area of study, 
for both theoretical and practical reasons. 
A number of findings support the presence 
of a sensory-discriminative dimension of 
pain processing that modulates its intensity 
and spatio-temporal characteristics, and an 
affective-motivational dimension associ-
ated with its negative valence and unpleas-
antness (30). 
The results of various studies converge to 
suggest that mood selectively alters the 
affective dimension of pain, as demon-
strated by Rainville (31) who showed that 
pain unpleasantness was more affected by 
emotions than pain intensity in a group 
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of healthy volunteers. A functional mag-
netic resonance imaging (fMRI) study has 
endorsed these findings by showing that 
the extent of depressive symptoms and 
the presence of comorbid major depres-
sion are associated with the magnitude of 
neuronal activation in the brain regions 
that process the affective-motivational di-
mension of pain, and not its sensory-dis-
criminative aspects (32). This finding is 
supported by some clinical studies, which 
found that self-rated depressive symp-
toms, anxiety and catastrophising did not 
correlate with the ratings of clinical and 
experimental pain in FM patients. How-
ever, depressive symptoms and anxiety 
can lead to a poor perception of physical 
health and significantly impair the health-
related quality of life. (33, 34). In a sam-
ple of 500 patients with musculoskeletal 
pain, 54% reported pain only, 20% pain 
and depression, 3% pain and anxiety, and 
23% pain, depression and anxiety. This 
last group experienced the greatest pain 
severity and pain-related disability, with 
more than twice the number of disability 
days due to their pain (i.e. 42.6 days in the 
previous three months vs the 18.1 days of 
those without concurrent clinical depres-
sion or anxiety) (35).
Neural correlates of the relationship be-
tween depression and pain
The relationship between depression and the 
affective dimension of pain is not surprising 
because the brain areas involved in regulat-
ing mood significantly overlap with those 
processing the emotional aspects of pain. 
The brain system that has been most fre-
quently implicated in the pathophysiol-
ogy of depression is the extended medial 
prefrontal network (also called the ‘medial 
network’), a group of ventrally located re-
gions whose core components include the 
ventromedial prefrontal cortex, and the 
ventral and posterior regions of the cin-
gulate cortex (36). These brain structures 
are highly activated during conditions in 
which healthy subjects attend to their inter-
nal emotions or rest passively, a state that 
frequently focuses on autobiographical 
thoughts and memories (37), and become 
deactivated in response to demanding cog-
nitive tasks that require an external focus of 
attention (38, 39).
In agreement with research indicating that 
effective disengagement from self-refer-
ential and negative affective processing is 
impaired in depressed patients (40), fMRI 
studies assessing brain responses during 
emotion processing (41) and cognitive/ex-
ecutive tasks (42) have shown that patients 
with major depression fail to reduce activi-
ty in the medial prefrontal regions, and that 
this impairment is linked to the severity of 
their depressive symptoms. Another recent 
study (43) has shown that, even in response 
to painful stimuli, patients with major de-
pression fail to deactivate a region involv-
ing the subgenual-pregenual anterior cin-
gulate cortex (ACC) and adjacent medial 
prefrontal areas, with abnormal persistence 
of activity during pain stimulation.
These findings suggest the presence of 
increased processing of internal somatic 
and visceral stimuli in major depressive 
patients that is consistent with enhanced 
self-focused attention and a reduction in 
the resources destined to external stimula-
tion, including painful stimuli. Given the 
role of the sub-genual ACC in maintaining 
self-focused attention, the reduced deacti-
vation in this region could explain the par-
adoxical phenomena of increased somatic 
complaints in depressive patients and the 
repeatedly described decreased pain per-
ception during experimentally delivered 
painful stimulation of the skin (44).
The ACC and the regions including the pa-
rietal operculum and posterior insula (PO/
PI) have also been identified as central 
cortical loci in regulating the emotional 
and behavioural reaction to pain. (45). It 
is thought that the ACC is a key structure 
that contributes to pain unpleasantness, as 
suggested by human observations showing 
that surgical ablation of the ACC signifi-
cantly reduces pain unpleasantness without 
affecting the ability to detect the intensity 
or location of pain (46). The role of the 
ACC is further supported by the observa-
tion that specific manipulation of pain un-
pleasantness leads to significant changes in 
ACC activity, whereas the manipulation of 
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pain intensity mainly leads to changes in 
the primary somatosensory cortex (31).
The ACC is not only involved in mediating 
the affective components of pain, but also 
mediates the anticipation of pain (47). In 
normal subjects, the uncertain expectation 
of painful stimulation enhances the brain re-
sponses to non-painful warm stimulation in 
the ACC and PO/PI (i.e. the expectation of 
painful stimulation amplifies the perceived 
unpleasantness of even innocuous stimu-
lation), whereas it does not influence per-
ceived pain intensity (48). Increased activa-
tion within the amygdale and the ACC dur-
ing the anticipation of pain has been demon-
strated in unmedicated subjects with current 
depression (49). These inappropriately large 
responses to anticipated pain suggest an 
exaggerated emotional distress or affective 
bias in the pain experience of patients with 
major depression patients, even before the 
actual painful stimulation occurs and even 
though the perception of pain intensity is 
not altered. This observation suggests that 
the difference between expected and actual 
body experiences may be greater in subjects 
with major depression. This is in line with 
the assumptions of cognitive models of de-
pression that depressed patients negatively 
bias their expectations, perceptions and 
memories, and may represent a neural cor-
relate of their hypervigilant monitoring of 
negative information (50).
The neuroimaging techniques used to as-
sess the cerebral response to painful stimu-
lation have also been used to investigate the 
effects of antidepressants. In comparison 
with untreated control subjects, patients 
with major depression treated with dulox-
etine show an improvement in core depres-
sive symptoms that significantly correlates 
with a significant reduction in fMRI pain-
related activations and enhanced deactiva-
tions in regions characterised by the ab-
normal persistence of activity during pain 
stimulation (34).
Decreased limbic activity also seems to 
contribute to the effect of cognitive behav-
ioural therapy (CBT), a psychotherapeutic 
method that has been demonstrated to be 
effective on various forms of chronic pain 
(51). CBT is an approach that uses guided 
discovery to identify and challenge dis-
torted cognitions (i.e catastrophism) and 
dysfunctional beliefs (52), and maladap-
tive behavioural patterns such as the avoid-
ance used to prevent pain can be targeted 
by exposure-oriented interventions. The 
few studies that have investigated the neu-
ral correlates of CBT in pain patients have 
found that the clinical effect of CBT was 
associated with signiﬁcantly decreased 
resting-state activity in the limbic regions, 
including the para-hippocampal gyrus and 
cingulate cortex. It is possible that the de-
creased limbic activity in response to CBT 
reﬂects attenuated vigilance and attention 
to pain as both of these measures have been 
found to improve after treatment (53, 54).
n	 CONCLUSIONS
Current evidence supports the idea that de-
pression and FM are highly inter-related, 
with the co-existence of both being associ-
ated with a poor prognosis and greater dis-
ability than that observed in patients with 
either illness alone. Recent findings have 
shown that depression in patients with FM 
is often associated with symptoms of oppo-
site polarity, such as the heights of mood, 
thinking and behaviour characterising the 
bipolar spectrum of mood disorders. These 
have an important impact on the pharma-
cological management of FM and support 
the use of alternative treatments such as the 
use anticonvulsant or antipsychotic drugs.
Although the underlying mechanism medi-
ating the comorbidity of mood disorder and 
chronic pain is unknown, there is support 
for a model in which brain regions (includ-
ing the limbic and paralimbic prefrontal 
cortical areas) play a role in both syn-
dromes. These neurobiological links may 
provide the anatomical basis of the bidi-
rectional relationship between pain and de-
pression, with the symptoms of one wors-
ening the other and/or making the other 
more likely to develop. Moreover, a better 
understanding of the relationship between 
pain and depression may improve current 
treatment options and provide targets for 
new treatment strategies.
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